We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-1.06%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$136M
AUM Growth
-$26.8M
Cap. Flow
-$22.4M
Cap. Flow %
-16.5%
Top 10 Hldgs %
67.25%
Holding
41
New
7
Increased
7
Reduced
12
Closed
6

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$4.21M
2
FDMT icon
4D Molecular Therapeutics
FDMT
+$2.04M
3
ARGX icon
argenx
ARGX
+$1.66M
4
ALKS icon
Alkermes
ALKS
+$863K
5
KURA icon
Kura Oncology
KURA
+$796K

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$7.33M
2
MRSN
Mersana Therapeutics
MRSN
+$5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$4.51M
4
BCAB icon
BioAtla
BCAB
+$4.13M
5
KROS icon
Keros Therapeutics
KROS
+$3.86M

Sector Composition

Rank Sector Weight
1 Healthcare 94.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$655K 0.48%
6,000
– –
SVRA icon
27
Savara
SVRA
$1.22B
$388K 0.29%
+199,031
New +$448K
MRSN
28
DELISTED
Mersana Therapeutics
MRSN
$247K 0.18%
2,400
-35,600
-94% -$5M
VKTX icon
29
Viking Therapeutics
VKTX
$3.93B
$233K 0.17%
+14,000
New +$145K
KROS icon
30
Keros Therapeutics
KROS
$214M
$153K 0.11%
3,575
-76,425
-96% -$3.86M
HLVX
31
DELISTED
HilleVax
HLVX
$110K 0.08%
+6,664
New +$107K
KNTE
32
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$31.3K 0.02%
5,000
– –
NUVB.WS
33
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$10.9K 0.01%
90,832
– –
ARWR icon
34
Arrowhead Research
ARWR
$12.5B
– –
-41,029
Closed -$1.66M
BCAB icon
35
BioAtla
BCAB
$5.56M
– –
-10,000
Closed -$4.13M
FULC icon
36
Fulcrum Therapeutics
FULC
$291M
– –
-185,000
Closed -$1.35M
MLTX icon
37
MoonLake Immunotherapeutics
MLTX
$1.57B
– –
-93,500
Closed -$982K
PRTA icon
38
Prothena Corp
PRTA
$444M
– –
-9,300
Closed -$560K
PYXS icon
39
Pyxis Oncology
PYXS
$243M
– –
-669,158
Closed -$897K
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Acuta Capital Partners held 41 positions worth $136M, down 16% from $163M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Acuta Capital Partners withdrew a net $22.4M in Q1 2023, closing 6 positions and reducing 12 holdings. Its most notable exit was BioAtla, an estimated $4.13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in 4D Molecular Therapeutics worth $1.8M.

  • Acuta Capital Partners's largest Q1 2023 buy was 4D Molecular Therapeutics: 104,753 shares worth $1.8M.
  • Acuta Capital Partners added most to Apellis Pharmaceuticals in Q1 2023, an estimated $4.21M increase.
  • Acuta Capital Partners's biggest Q1 2023 reduction was Viridian Therapeutics, cutting an estimated $7.33M.
  • Acuta Capital Partners fully exited BioAtla in Q1 2023, selling an estimated $4.13M.
  • Acuta Capital Partners's ten largest holdings make up 67% of its $136M portfolio in Q1 2023.
  • Acuta Capital Partners opened 7 new positions and closed 6 in Q1 2023.
  • Acuta Capital Partners's portfolio value fell 16% quarter-over-quarter to $136M.

Based on Acuta Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.